Skip to content

Alligator Bioscience

  •  
    • Se
  • Startpage
  • About Alligator
    • Board of Directors
    • Senior Management
    • Career
  • Research and development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • Neo-X-PrimeTM
      • ALG.APV-527
      • ATOR-1017
      • Research projects
    • Scientific publications
    • Technology platform
      • Alligator-GOLD®
      • Alligator-FABTM
      • FIND®
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination Committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and owner information
    • Sharegraph
    • Analysts
    • Preferential Rights Issue Q2 2023
    • Preferential Rights Issue Q4 2021
    • Preferential Rights Issue Q1 2021
    • IPO
    • Financial reports
      • Interim reports
      • Year End Reports
      • Annual reports
    • Financial calendar
    • Presentations
  • Business Development
  • News
  • Press releases
  • Contact
  • Events

  1. Startpage
  2. News
  3. Corporate Action
Key downloads
Alligator Bioscience AB reports full year financial results for 2022 and for Q4 2022 and provides a business updateAlligator Bioscience AB reports financial results for the first 9 months of the year and for Q3 2022 and provides a business updateAlligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business updateBulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022Interim report January–March 2022
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
All IRRegulatoryReport
View as grid View as list
2023-03-22
Regulatory

Alligator intends to carry out a 91 percent secured rights issue of units of approximately SEK 199 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Continue reading
2022-03-31
Regulatory

Change in number of shares and votes in Alligator Bioscience AB

During the month of March, the number of shares and votes in Alligator Bioscience AB have increased due to directed issue and repurchase of ...
Continue reading
2022-03-22
Regulatory

Issue and repurchase of series C shares for performance-based share saving program

Pursuant to the authorization granted by the annual general meeting on 1 June 2021, the board of directors of Alligator Bioscience AB (”Alli ...
Continue reading
2021-12-30
Regulatory

Change in number of shares and votes in Alligator Bioscience AB

During December 2021, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the completion of ...
Continue reading
2021-10-22

Alligator enters into agreements on subscription commitments with board members and senior executives

The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or "the Company") has previously, subject to approval ...
Continue reading
2021-02-26
Regulatory

Change in number of shares and votes in Alligator Bioscience AB

During February 2021, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the completion of ...
Continue reading
2020-12-30

Alligator Bioscience publishes prospectus in connection with forthcoming rights issue

The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or the "Company") has, in connection with the rights i ...
Continue reading
2020-12-15
Regulatory

Alligator carries out a fully guaranteed rights issue of approximately SEK 86m

The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or the "Company") has today, based on the authorizatio ...
Continue reading
2017-03-31
Regulatory

Change in number of shares and votes in Alligator Bioscience AB (publ)

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that the number of shares and votes in Alligator Bios ...
Continue reading

Posts navigation

Older posts
  1. Startpage
  2. News
  3. Corporate Action
About Alligator

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase 2 studies and beyond.

Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).

Links
  • About Alligator
  • R&D
  • Corporate governance
  • Investors
  • News
  • Business Development
  • Privacy Policy
Contact us

Alligator Bioscience AB Medicon Village Scheelevägen 2 SE-223 81 Lund Sweden

Phone:
+ 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com
bd@alligatorbioscience.com

Follow us

  

Email subscription

Subscribe to get our pressreleases and investor alerts by email from Alligator Bioscience.

Subscribe

  • © Copyright 2019 – Alligator Bioscience AB

  • Privacy Policy | Use of Cookies |  Change your cookie settings here.

  • Disclaimer Market data could be delayed. Delivered by Modular Finance.

Cookies
We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.
Settings Accept all
Cookies
Do your settings below. Or read our cookie policy.
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all